FindTrial
Sign In

My study is about comparing the changes in blood pressure in patients having BP 140/90 to 160/100 mmHg with Vitamin D levels of 20 to 29 ng/mL taking standard of treatment which is tablet Telmisartan 40mg alone in one group and tablet Telmisartan 40mg with Vitamin D supplementation in another group

A study to compare the efficacy of Telmisartan alone versus Telmisartan and Vitamin D supplementation on blood pressure in patients with stage I essential hypertension along with Vitamin D insufficiency Randomized controlled study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097592
Enrollment
84
Registered
2025-11-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: tablet Telmisartan 40 mg OD alone versus tablet Telmisartan 40 mg OD plus Vitamin D supplementation: Tablet Telmisartan 40 mg OD at night along with Vitamin D 60,000 IU sachets once per

Sponsors

nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to give written informed consent Patients of either sex aged above 18 years and less than 60 years Patients with newly diagnosed stage I essential hypertension as per JNC 8 guidelines BP more than 140 by 90 mmHg to less than 160 by 100 mmHg not on any antihypertensive medications Patients with vitamin D insufficiency 25 OH D levels of 20 to 29 ng per mL

Exclusion criteria

Exclusion criteria: Pregnant and lactating mothers Patients with secondary hypertension Patients with any other co-existing medical illness such as type 2 diabetes mellitus, dyslipidemia, cardiac, pulmonary, renal and hepatic disorders Patients who are on anticonvulsants, glucocorticoids, rifampicin, HAART therapy Patients with hypersensitivity to study medication

Design outcomes

Primary

MeasureTime frame
mean reduction in systolic/diastolic blood pressureTimepoint: at baseline, 4 weeks, 8 weeks—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr Medhaveeni

Banglore medical college and research institute

geethaanantharamaiah@gmail.com9886224085

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026